SCHEMBL3401045

SCHEMBL3401045

CCc1c(C(=O)O)c(C(F)F)nn1C

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 4/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
PTGER2 P43116 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3399074 0.84
SCHEMBL437422 0.77 PTGER4 (0.37) PTGER4MEN1KMT2APTGER2
SCHEMBL3401329 0.77 KDM4E (0.40) PTGER4MEN1KMT2APTGER2POLB
SCHEMBL15165797 0.77 PTGER4 (0.35) PTGER4MEN1KMT2APTGER2
SCHEMBL28359811 0.77 LMNA (0.41) PTGER4KMT2A
SCHEMBL437373 0.76 L3MBTL1 (0.40) PTGER4MEN1KMT2APOLB
SCHEMBL20550872 0.76 PTGER4 (0.34) PTGER4MEN1KMT2APTGER2
SCHEMBL20996474 0.76 PTGER4 (0.34) PTGER4MEN1KMT2APTGER2
Hydrochloric Acid SCHEMBL28753862 0.76 PTGER4 (0.37) PTGER4MEN1KMT2APTGER2
SCHEMBL15158194 0.73 PTGER4 (0.37) PTGER4MEN1KMT2APTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11299463-B2 Process for the manufacture of pyrazoles or pyrimidones FUJIAN YONGJING TECHNOLOGY CO., LTD. (CN) 2022-04-12 US disclosed
EP-3650443-A1 CONTINUOUS FLOW SYNTHESIS OF FLUORINATED OR NON-FLUORINATED PYRAZOLES Fujian Yongjing Technology Co., Ltd. (CN) 2020-05-13 EP disclosed
US-20200140390-A1 Process for the Manufacture of Pyrazoles or Pyrimidones FUJIAN YONGJING TECHNOLOGY CO., LTD. (CN) 2020-05-07 US disclosed
EP-2257532-B1 METHOD FOR REGIOSELECTIVE SYNTHESIS OF 1-ALKYL-3-HALOALKYL-1-PYRAZOL-4-CARBONIC ACID DERIVATIVES BAYER CROPSCIENCE AG (DE) 2013-05-29 EP disclosed
EP-2257532-A1 PROCESS FOR THE REGIOSELECTIVE SYNTHESIS OF L-ALKYL-3-HALOALKYLPYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES BAYER CROPSCIENCE AG (DE) 2010-12-08 EP disclosed
EP-2057126-B1 PROCESS FOR PREPARING 3-DIHALOMETHYLPYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES BAYER CROPSCIENCE AG (DE) 2010-11-10 EP disclosed
EP-2133341-A1 Method for regioselective synthesis of 1-alkyl-3-haloalkyl-1-pyrazol-4-carbonic acid derivatives Bayer CropScience AG (DE) 2009-12-16 EP disclosed
WO-2009112157-A1 PROCESS FOR THE REGIOSELECTIVE SYNTHESIS OF L-ALKYL-3-HALOALKYLPYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2009-09-17 WO disclosed
EP-2100883-A1 Method for regioselective synthesis of 1-alkyl-3-haloalkyl-1-pyrazol-4-carbonic acid derivatives Bayer CropScience AG (DE) 2009-09-16 EP disclosed
EP-2057126-A2 PROCESS FOR PREPARING 3-DIHALOMETHYLPYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES Bayer CropScience AG (DE) 2009-05-13 EP disclosed
WO-2008022777-A2 PROCESS FOR PREPARING 3-DIHALOMETHYLPYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES BAYER CROPSCIENCE AG (DE) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200140390-A1 Process for the Manufacture of Pyrazoles or Pyrimidones DHFR, CYP4X1, CYP2F1 PTGER4 357/4885MEN1 4644/4885KMT2A 733/4885
US-11299463-B2 Process for the manufacture of pyrazoles or pyrimidones DHFR, CYP4X1, CYP2F1 PTGER4 379/4885MEN1 4620/4885KMT2A 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.